← All trials
NCT02341989
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2015
- Primary completion
- Dec 1, 2020
- Completion date
- Dec 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 348
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Norwegian University of Science and TechnologyLead sponsor
- Lund UniversityCollaborator
- Norwegian University of Science and TechnologyOverall official - principal investigator
- University Hospital of North NorwayCollaborator
- Linkoping UniversityCollaborator
- University of BergenCollaborator
- Osaka UniversityCollaborator
- University of GothenburgCollaborator
- Uppsala UniversityCollaborator
- Norrlands UniversityCollaborator
- Lund UniversityOverall official - principal investigator
- Karolinska InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.